A Study of SYS6020 Injection in Refractory Active Systemic Lupus Erythematosus

NCT ID: NCT06694298

Last Updated: 2024-11-19

Basic Information

• Recruitment Status: NOT_YET_RECRUITING
• Clinical Phase: PHASE1
• Total Enrollment: 50 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2024-12-26
• Study Completion Date: 2029-01-29

Brief Summary

This study aimed to observe the safety and tolerability of SYS6020 in adult participants with refractory active systemic lupus erythematosus, determine the recommended dose (RD) that may be explored for subsequent studies, and preliminly evaluate the clinical efficacy of this product,and explore the pharmacokinetics and immunogenicity of SYS6020 injection in those participants.

Conditions

Refractory Active Systemic Lupus Erythematosus

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

SYS6020

Group Type: EXPERIMENTAL

SYS6020

Intervention Type: DRUG

BCMA Chimeric Antigen Receptor T Cell（SYS6020）Injection Intravenous infusion

Interventions

SYS6020

BCMA Chimeric Antigen Receptor T Cell（SYS6020）Injection Intravenous infusion

Intervention Type: DRUG

Other Intervention Names

BCMA Chimeric Antigen Receptor T Cell（SYS6020）Injection

Eligibility Criteria

Inclusion Criteria

• 1. Age ≥18 years old, ≤70 years old;
• 2. SLE is diagnosed according to SLICC 2012 or EULAR/ACR 2019 revised criteria.
• 3. Patients are required to have received glucocorticoid combined with immunosuppressive agents and/or biological agents for more than 3 months, with a stable dose for more than 2 weeks, and the disease is still in an active state.
• 4. Antinuclear antibody, anti-ds-DNA antibody and/or anti-Smith antibody are positive.
• 5. SLEDAI-2K score≥7.
• 6. BILAG2004 meets one of the following two criteria:a）BILAG grade A is defined as ≥1 organ system；b）BILAG grade B is defined as ≥2 organ systems
• 7. PGA > 1.0;

Exclusion Criteria

• 1. Severe lupus nephritis within 8 weeks before screening;
• 2. SLE or non-SLE-related central nervous system disease or lesion within 8 weeks before screening;
• 3. uncontrolled lupus crisis within 8 weeks before screening;
• 4. clinically significant central nervous system diseases or pathological changes other than lupus before screening;
• 5. vasculitis or inflammatory arthritis or skin disease other than SLE or at screening;
• 6. complicated with other autoimmune diseases;
• 7. A B-cell-targeting agent have been used or is planned to be used within 8 weeks before screening，
• 8. received Renal Replacement Therapy（RRT）within 3 months before the screening period or anticipates the need for RRT during the study period;
• 9. participants who will undergo major surgery or invasive intervention within 4 weeks prior to apheresis or plan for systemic or local tumor resection during the study period;
• 10. participants with a known allergy, hypersensitivity, intolerance, or contraindications to SYS6020 or any component of the drugs that may be used in the study,
• 11. active bacterial, fungal, or viral infection within 2 weeks before apheresis;

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 70 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Other Identifiers

SYS6020-003

Identifier Type: -

Identifier Source: org_study_id